Rosatom has initiated the creation of an international platform for the development of radiopharmaceuticals based on terbium-161, which can improve the effectiveness of cancer treatment and reduce the side effects of therapy. This was announced at the "World Nuclear Week" forum.
We propose to form a multinational expert group that will combine technologies for the production of the radionuclide, methods for its purification, the development of promising radiopharmaceuticals, and the exchange of clinical results
The project is designed for three years with the possibility of extension and includes regular publication of results in peer-reviewed scientific journals.
Technologies used for the production and use of lutetium-177 can be adapted for terbium-161. The additional effect of terbium-161 electrons allows to increase the effectiveness of therapy with minimal damage to healthy tissues.
The scientific division of Rosatom manages 12 research centers, nine reactors, and more than 700 experimental facilities, and produces over ten radiopharmaceuticals. A large radiopharmaceutical plant is under construction in Obninsk, scheduled to launch next year.
Read more on the topic:
Now on home
The service contains data on 45,000 fraudulent sites
The state has accelerated the introduction of unmanned solutions, integrating them into the real sector of the economy
Modernized engines may equip the Lada Azimut crossover
The price is 132 billion 265.8 million rubles
The manufacturer plans to strengthen its lineup of light commercial vehicles
The production of carbon fiber was organized in the shortest possible time
Electric vans will speed up the repair of urban transport infrastructure
Countries are working to synchronize regulations in the field of AI
The service's average daily audience is 55 million people
Stable Isomaterial Based on Metakaolin Has a Density Below 300 kg/m³
Re-identification quality improved twofold with new DynaMix method
Russians will be able to find out about debts online